Emerging Trends in Cell Banking (Technical Insights)

Trends in Master and Working Cell Baking

Regular Price: USD 3,950.00

Special Price USD 3,555.00

10% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 3,555.00

PAY BY INVOICE

Be the first to review this product

The execution of different test methods aiming to evaluate the stability and potency of biopharmaceutical products, as well as, their pharmacokinetic/pharmacodynamic (PK/PD) profiles, their characterization and comparison with other drugs, or the detection of antidrug antibodies (ADAs) or neutralizing antibodies (NAB), represent critical stages in drug discovery and development. On that note, cells and cell-based reagents constitute the foundations of most operational challenges. Indeed, cultured cells are frequently used to generate monoclonal antibodies (MAbs), enzymes, or substrates to be then utilized in other types of tests, such as ligand binding and enzymatic assays, thereby requiring distinct characteri

Table of Contents

Executive SummaryResearch ScopeResearch MethodologyKey FindingsTechnology Snapshot and TrendsTechnology Overview Technology Process Overview Technology Value ChainTechnology CapabilityTechnology CapabilityTechnology CapabilityTechnology CapabilityImpact Assessment and AnalysisMarket Impact of Key Innovations Market Impact of Key Innovations Market Impact of Technology Market Impact of Technology Diffusion of Innovations and Needs AssessmentTechnology Adoption Cycle Technology Adoption CycleTechnology Adoption Cycle Technology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleTechnology Adoption CycleOpportunity Evaluation and RoadmappingScenario Modelling and Emerging OpportunitiesDemand Side AnalysisDemand Side AnalysisBiophramas are increasing their partnerships with CMOs, for storing their proprietary cell lines and the development of novel cell lines.Company Profiles (continued)Company Profiles (continued)Company Profiles (continued)Company Profiles (continued)Company Profiles (continued)Key Contacts, Key Patents, andDecision Support DatabaseKey ContactsKey Contacts (continued)Key Contacts (continued)Key Contacts (continued)PatentsPatents (continued)DSD–Government Healthcare Expenditure (Billion USD)DSD–Pharmaceutical R&D Expenditure as a Percentage of Pharmaceutical MarketDSD–Pharmaceutical R&D Expenditure (Million USD)DSD–Total Healthcare Expenditure (Billion USD)DSD–Venture Capital Investment in Biotech R&D (Million USD)Legal DisclaimerThe Frost & Sullivan StoryWho is Frost & SullivanWhat Makes Us UniqueTEAM MethodologyOur Global Footprint 40+ Offices




Related Research

Release Date : 29-Apr-2016

Region : Global

Release Date : 30-Mar-16

Region : Global

Release Date : 30-Mar-16

Region : Global

Release Date : 30-Sep-2015

Region : Europe

Release Date : 29-Sep-2015

Region : Global

Release Date : 29-Jun-15

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.